A woman’s guide to talking with her hematologist about hemophilia B provides information to help you feel more confident discussing your symptoms. Download the guide now »

    women decoHeroines of Hemophilia B

    Honoring the women who have fought against hemophilia B—either for themselves, or in the care and treatment of others.

    Tell us about the heroine in your life »


    Your Heroine

    Do you know a special woman who deserves to be recognized as a Heroine of Hemophilia B?

    Tell us about her



    Patient and mother of son with hemophilia B

    “Erica is amazing. She makes sure her son is taken care of, and she makes sure she’s taken care of, too! Erica won’t let anything hold either of them back!”



    Patient with hemophilia B

    “When Joel warned her dentist about her bleeding disorder, they dismissed it as ‘anxiety’. Luckily, Joel knows how to stand up for herself. She is a fierce advocate for women with hemophilia B.


    The stories you see here have been submitted by visitors to IXINITY.com. They do not necessarily reflect the views of Medexus Pharma. Except for correcting obvious errors, and taking out things we cannot say, the stories of these heroines appear just as they were written.

    Discover more remarkable women

    Tell us about the heroine in your life.

    Here’s your chance to share the story of that special woman who either has hemophilia B, or has made a difference in the life of someone who has hemophilia B. Express your gratitude. Who knows, maybe she’ll end up featured here, so everyone else can see how wonderful she is!



    You must be thirteen (13) years or older to enroll. If you are aged 13 to 18, you should get your parent’s or guardian’s permission before providing your personal information.

    Medexus Pharma, Inc. and companies working on its behalf may disclose the personal information you provide us to a third-party vendor in order to deliver the information you are requesting about Medexus, our services and programs, or other topics of interest. We may also share your information with regulatory authorities or contact you regarding market research opportunities.

    Your personal information will be processed and stored in electronic databases controlled by or on behalf of Medexus. We will not sell or transfer your personal information to any unrelated third party for marketing purposes without your express permission.

    To learn more about how your personal information is used or if you decide that you no longer want to receive information from Medexus, please visit www.ixinity.com/privacy-terms-of-use/.

    Support for women with hemophilia B

    Discover how the support and care provided to women with hemophilia B has affected the lives of patients, their caregivers, and families.

    In February 2020, Medexus Pharma, Inc. acquired Aptevo BioTherapeutics LLC.

    The Facts

    Among women who carry the gene for hemophilia B:


    57% have heavy periods vs 9%-14% of the general population6


    There exists twice the risk of prolonged bleeding from small wounds vs non-carriers7


    21% reported spontaneous bleeding after trauma (small wounds) vs 9% of non-carriers7

    A woman’s guide

    Medexus Pharma worked with women who have hemophilia B to create a guide that focuses on how this condition affects women, girls, and their families. Download this guide today.


    Real patient stories

    Listen in as real patients— including Heidi, Erica, and Joel—share their experiences with hemophilia B.

    Watch Now
    References: 6. Babul-Hirji R, Brownlow M, Kirk A. Little L, Stewart P. All About Carriers: A Guide for Carriers of Hemophilia A and B. Canadian Hemophilia Society. 2007;1-136. 7. Plug I, Mauser-Bunschaten EP, Briicker-Vriends AHJT, et al. Bleeding in carriers of hemophilia. Blood. 2006;108(1):52-56.



    What is IXINITY?

    IXINITY [coagulation factor IX (recombinant)] is a medicine used to replace clotting factor (factor IX) that is missing in adults and children with hemophilia B. Hemophilia B is also called congenital factor IX deficiency or Christmas disease. Hemophilia B is an inherited bleeding disorder that prevents clotting. For children and adults, your healthcare provider may give you IXINITY for on-demand treatment and control of bleeding episodes, when you have surgery, or for routine prophylaxis to prevent bleeding episodes.

    IXINITY is not indicated for induction of immune tolerance in patients with hemophilia B.


    • You should not use IXINITY if you are allergic to hamsters or any ingredients in IXINITY.

    • You should tell your healthcare provider if you have or have had medical problems, take any medicines, including prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies, have any allergies, including allergies to hamsters, are nursing, are pregnant or planning to become pregnant, or have been told that you have inhibitors to factor IX.

    • You can experience an allergic reaction to IXINITY. Contact your healthcare provider or get emergency treatment right away if you develop a rash or hives, itching, tightness of the throat, chest pain, or tightness, difficulty breathing, lightheadedness, dizziness, nausea, or fainting.

    • Your body may form inhibitors to IXINITY. An inhibitor is part of the body's defense system. If you develop inhibitors, it may prevent IXINITY from working properly. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for development of inhibitors to IXINITY.

    • If you have risk factors for developing blood clots, the use of IXINITY may increase the risk of abnormal blood clots.

    • Call your healthcare provider right away about any side effects that bother you or do not go away, or if your bleeding does not stop after taking IXINITY.

    • The most common side effect that was reported with IXINITY during clinical trials was headache.

    • These are not all the side effects possible with IXINITY. You can ask your healthcare provider for information that is written for healthcare professionals.

    For more information about IXINITY, please see full Prescribing Information.

    You are encouraged to report adverse events related to Medexus Pharma products by calling 1-844-859-6675. If you prefer, you may contact the Food and Drug Administration directly. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.